HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 7,393-7,404 of 27,277
Drug study icon
CompletedNCT00839852

Cariprazine in people with Chronic Stable Schizophrenia

What is this study about?

Researchers studied Cariprazine to find out how it affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Costa Mesa
SchizophreniaMedication studyAges 18–61
Countries
United States, India, Malaysia, + 2 others
Sponsor
Forest Laboratories
Drug study icon
CompletedNCT01412060

Cariprazine in the Prevention of Relapse of Symptoms in people with Schizophrenia

Official study title

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–60
Countries
United States, India, Romania, + 2 others
Sponsor
Forest Laboratories
Drug study icon
CompletedNCT06340958

CLE-100 (Oral Esketamine) for depression

What is this study about?

This study evaluated the safety and effectiveness of CLE-100 for people with depression.

This study has finished and is no longer accepting participants.

Multiple locations, including La Jolla
DepressionMedication studyAges 18–65
Countries
United States
Sponsor
Clexio Biosciences Ltd.
Other study type icon
CompletedNCT04294719

Cognitive Adaptation Training in Inpatient Forensic Environments

Official study title

A Study of Cognitive Adaptation Training in Inpatient Forensic Environments

This study has finished and is no longer accepting participants.

In Toronto
SchizophreniaObservational studyAges 18+
Countries
Canada
Sponsor
Centre for Addiction and Mental Health (Hospital / academic medical center)
Drug study icon
CompletedNCT01940978

Combination Therapy in Children With ADHD

Official study title

A Double-Blind Placebo-Controlled Study of Combination Therapy in Children With ADHD

This study has finished and is no longer accepting participants.

In Van Nuys
ADHDMedication studyAges 6–12
Countries
United States
Sponsor
Douglas Sears
Drug study icon
CompletedNCT00564954

Extended-release dexmethylphenidate for children with ADHD

About this title

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

Read the official source — NCT00564954
Official study title

A Randomized, Multi-center, Double-blind, Cross-over Study Comparing the Efficacy and Safety of Focalin® XR 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
ADHDMedication studyAges 6–12
Countries
United States
Sponsor
Novartis Pharmaceuticals
Other study type icon
CompletedNCT01729026

Dog Adoption in Veterans With PTSD (PTSD)

Official study title

A Study of Dog Adoption in Veterans With Posttraumatic Stress Disorder

This study has finished and is no longer accepting participants.

In San Antonio
PTSDInterventional studyAges 18+
Countries
United States
Sponsor
VA Office of Research and Development (Government agency)
Drug study icon
CompletedNCT00796432

Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone

Official study title

Open-label Positron Emission Tomography (PET) Study of Central D2-receptor Occupancy in Healthy Subjects Following a Single Oral Dose of OROS Paliperidone

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 20–45
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00086320

Paliperidone extended-release to help prevent schizophrenia symptoms from returning

About this title

A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Read the official source — NCT00086320
Official study title

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Evaluating Paliperidone Extended Release Tablets in the Prevention of Recurrence in Subjects With Schizophrenia

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–65
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.